Jilin Aodong Pharmaceutical Group Co., Ltd.
000623
Rangering i aksjer
#4951
Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally... Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally focusing on the production and distribution of a broad spectrum of pharmaceutical goods. Its product line encompasses various drug forms like oral liquids, injections, capsules, granules, pills, and tablets, as well as traditional Chinese herbal medicines, powders, syrups, and spirits. The company also produces specialized medicinal products, including enzymes, biochemical drugs, and plant-based chemical medicines. In addition to its core pharmaceutical activities, Jilin Aodong diversifies its operations across several other sectors. These include highway construction and toll management, animal husbandry, the creation of specialty chemicals, and the provision of heat and water. The company further engages in the wholesale, retail, and distribution of medicines, packaging design and printing, the manufacturing of medicinal packaging materials, and delivers information consulting and advertising design solutions. Founded in 1957, its corporate headquarters are situated in Dunhua, China.
Aksjekurs
$2.55
Markedsverdi
$3.05B
Endring (1 dag)
3.33%
Endring (1 år)
-11.84%
Land
CN
Handel Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)
Kategori
Healthcare
Inntekter for Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)
Inntekter i Jun 2026 TTM: $450.70M
Ifølge Jilin Aodong Pharmaceutical Group Co., Ltd. sine nyeste økonomiske rapporter er selskapets nåværende resultat $450.70M. I 2023 hadde selskapet et resultat på $211.93M, en nedgang sammenlignet med resultatet i 2022, som var $249.47M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Jilin Aodong Pharmaceutical Group Co., Ltd. fra 2000 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $450.70M | 116.23% |
| 2024 | $208.44M | -1.65% |
| 2023 | $211.93M | -15.05% |
| 2022 | $249.47M | -10.25% |
| 2021 | $277.96M | 5.78% |
| 2020 | $262.76M | 23.65% |
| 2019 | $212.51M | 47.80% |
| 2018 | $143.78M | -51.61% |
| 2017 | $297.11M | 18.54% |
| 2016 | $250.63M | -39.05% |
| 2015 | $411.21M | 71.49% |
| 2014 | $239.79M | 22.14% |
| 2013 | $196.32M | 79.35% |
| 2012 | $109.46M | -71.97% |
| 2011 | $390.52M | 99.92% |
| 2010 | $195.34M | -5.51% |
| 2009 | $206.72M | 55.20% |
| 2008 | $133.20M | -52.18% |
| 2007 | $278.56M | 315.81% |
| 2006 | $66.99M | 289.48% |
| 2005 | $17.20M | -21.22% |
| 2004 | $21.83M | 20.73% |
| 2003 | $18.09M | 43.68% |
| 2002 | $12.59M | 67.81% |
| 2001 | $7.50M | -36.78% |
| 2000 | $11.87M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 291.51% |
IN
|
